证券代码:300238 证券简称:冠昊生物 公告编号:2023-053 冠昊生物科技股份有限公司 关于参加 2023 广东辖区上市公司投资者网上集体接待日活动的 公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整,没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流,冠昊生物科技股份有限公司(以下简称 "公司")将参加由广东证监局、广东上市公司协会联合举办的"2023 广东辖区 上市公司投资者网上集体接待日活动",现将相关事项公告如下: 本次投资者网上集体接待日活动将采用网络远程的方式举行,投资者可登录 "全景路演"网站(https://rs.p5w.net)参与本次互动交流,活动时间为 2023 年 9 月 19 日(星期二)15:45—17:00。 届时公司高管将在线就公司 2023 年半年度业绩、公司治理、发展战略、经 营状况和可持续发展等投资者关心的问题,与投资者进行沟通与交流。 欢迎广大投资者积极参与。 特此公告。 冠昊生物科技股份有限公司董事会 2023 年 9 月 15 日 ...

Financial Performance - Guanhao Biotech reported a revenue of CNY 500 million for the first half of 2023, representing a year-on-year increase of 15%[18]. - The company achieved a net profit of CNY 100 million, with a profit margin of 20%[18]. - The company aims to achieve a revenue target of CNY 1 billion for the full year 2023, reflecting a growth rate of 20%[18]. - The company achieved operating revenue of CNY 210,814,871.09, an increase of 3.91% compared to the same period last year[24]. - Net profit attributable to shareholders reached CNY 30,743,377.17, a significant increase of 112.60% year-on-year[24]. - The total profit for the first half of 2023 was CNY 33,893,615.23, compared to a total loss of CNY 237,568,867.85 in the same period last year[157]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥7,646,425.78, compared to a decrease of ¥74,215.06 in the previous year, marking a 10,403.06% change[54]. - The total comprehensive income for the first half of 2023 was CNY 31,421,773.88, a recovery from a loss of CNY 243,273,320.32 in the same period last year[158]. Market Expansion and Product Development - Guanhao Biotech plans to launch three new products in the next quarter, focusing on regenerative medicine[18]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[18]. - The company is exploring potential acquisitions to strengthen its product portfolio and expand its capabilities in the biotech sector[18]. - The company plans to continue focusing on market expansion and new product development to drive future growth[157]. - The company is exploring potential mergers and acquisitions to accelerate growth and diversify its product offerings[171]. Research and Development - Research and development expenses increased by 20%, totaling CNY 50 million, to support innovation in new technologies[18]. - The company has allocated 30.7 million for research and development in the first half of 2023, which is a 31.4% increase from the previous period[171]. - The company has successfully passed the acceptance of the national key research and development project for joint cartilage regenerative implant materials[40]. - The company is actively developing personalized products in the cell storage category to meet market demands[45]. - The company is advancing clinical research on mesenchymal stem cell treatments in collaboration with several medical institutions[45]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[4]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[72][73][74]. - The company has not reported any fundraising activities during the reporting period[71]. - The company has not engaged in any major related party transactions during the reporting period[110]. - The company has maintained a clean slate regarding major operational contracts, with no significant risks or changes reported[124]. Corporate Governance and Compliance - The company emphasizes its mission to contribute to human health and quality of life through innovation in regenerative medicine[92]. - The company maintains a commitment to protecting the rights of shareholders and creditors, ensuring transparency in information disclosure[93]. - The company has established a comprehensive quality management system to ensure high-quality products and services, emphasizing the importance of product safety and stability for consumer protection[97]. - The financial statements have been prepared in accordance with the accounting standards set by the Ministry of Finance, ensuring compliance and accuracy[186]. - The company has a unified accounting policy across all subsidiaries, which is crucial for the preparation of consolidated financial statements[192]. Legal and Regulatory Matters - The company reported a significant lawsuit involving an amount of 10,510,000 RMB, which is currently in the first instance and has not yet been adjudicated[109]. - A subsidiary of the company is involved in arbitration with a claim amount of 5,392,920 RMB, expected to be heard in February 2024[109]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[92]. - The semi-annual financial report has not been audited[107]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 37,634[134]. - Guangdong Zhiguang Biotechnology holds 20.76% of the shares, totaling 55,044,822 shares, all of which are pledged and frozen[134]. - The company has not reported any changes in share capital or stock buyback progress during the reporting period[132]. - The company has not engaged in any repurchase transactions among its top ten shareholders during the reporting period[136].

证券代码：300238 证券简称：冠昊生物 冠昊生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|---------------|-------------|--------|----------| | | | | 编号： | 2023-003 | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活 | □媒体采访 | ☑业绩说明会 | | | | 动类别 | □新闻发布会 | □路演活动 | | | □现场参观 □其他 参与单位名称 及人员姓名 参与冠昊生物 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 5 日 15:00--17:00 地点 价值在线网络互动 董事长 张永明先生 独立董事 韩俊梅女士 上市公司接待 副董事长、总经理 王新志先生 人员姓名 董事、副总经理兼董事会秘书 赵军会女士 财务负责人 张伟坤先生 为便于广大投资者能够更加全面、深入了解公司的生产经营 情况，公司于 2023 年 5 月 5 日下午 15:00-17:00 在"价值在线" 举行 2022 年度网 ...

Financial Performance - The net profit attributable to shareholders for 2022 was -307.84 million yuan, a decrease of 517.76% compared to the previous year[4]. - The total operating revenue for 2022 was 377 million yuan, down 22.84% year-on-year, with artificial crystal revenue decreasing by 74.68% and biological membrane revenue decreasing by 22.92%[5]. - The company's operating revenue for 2022 was ¥377,285,014.20, a decrease of 22.84% compared to ¥488,981,886.96 in 2021[20]. - The net profit attributable to shareholders for 2022 was -¥307,836,656.76, representing a decline of 517.76% from ¥73,687,006.12 in 2021[20]. - The cash flow from operating activities for 2022 was ¥70,983,730.69, down 42.00% from ¥122,394,243.74 in 2021[20]. - The total assets at the end of 2022 were ¥670,209,400.26, a decrease of 39.00% from ¥1,098,737,109.35 at the end of 2021[20]. - The basic earnings per share for 2022 was -¥1.16, compared to ¥0.28 in 2021, reflecting a decline of 514.29%[20]. - The company reported a weighted average return on equity of -48.51% for 2022, down 58.24% from 9.73% in 2021[20]. - The net profit after deducting non-recurring gains and losses for 2022 was -¥331,643,797.56, a decrease of 748.43% from ¥51,145,907.07 in 2021[20]. - The total net assets attributable to shareholders at the end of 2022 were ¥485,310,208.77, down 38.09% from ¥783,920,552.56 at the end of 2021[20]. Impairment and Losses - The company recognized an inventory impairment loss of 69.05 million yuan and goodwill impairment loss of 214.33 million yuan due to the early termination of the distribution agreement for its subsidiary, Zhuhai Xiangle Medical Equipment Co., Ltd.[4]. - Investment losses from joint ventures and associates amounted to 11.29 million yuan, with long-term equity investment impairment losses of 30.36 million yuan due to economic downturns[4]. - The company recorded an asset impairment loss of CNY 214.33 million related to the acquisition of Zhuhai Xiangle[47]. - The company's non-recurring gains and losses impacted the net profit attributable to shareholders by CNY 23.81 million in 2022[47]. Revenue Breakdown - The medical device segment generated ¥286,215,041.32, accounting for 75.86% of total revenue, down 30.09% from ¥409,408,769.43 in 2021[58]. - The pharmaceutical segment saw an increase in revenue to ¥34,354,885.49, representing 9.11% of total revenue, up 14.79% from ¥29,927,387.48 in 2021[58]. - Revenue from Benvimod cream reached CNY 34.35 million, an increase of 14.79% compared to the previous year[46]. - Revenue from cell technology services was CNY 40.45 million, up 73.88% year-over-year[46]. - Revenue from neurosurgery agency products amounted to CNY 79.82 million, reflecting an 11.81% increase from the prior year[46]. Research and Development - The company invested CNY 57,899,997.51 in R&D in 2022, representing 15.35% of its operating revenue, an increase from 10.06% in 2021[72]. - The number of R&D personnel remained stable at 70, with a slight decrease in the proportion of R&D staff from 12.60% in 2021 to 12.00% in 2022[72]. - The company applied for 7 new patents in 2022, bringing the total to 118 authorized patents, including 85 invention patents and 33 utility model patents[72]. - The company has established a cell and stem cell research and application platform, with two GMP-certified cell production lines[44]. - The company is conducting clinical research for a new biological dura mater repair material aimed at enriching its biomaterials product line[71]. Market and Growth Opportunities - The global pharmaceutical expenditure is projected to reach $1.5 trillion by 2025, with an average growth rate of 4.6% over the next five years[36]. - The Chinese pharmaceutical market is expected to grow at a rate of 14%-17%, surpassing 5.3 trillion yuan by 2025[36]. - The market size for psoriasis treatment in China is anticipated to reach 20.87 billion yuan by 2025, with a compound annual growth rate of 35% from 2020 to 2025[36]. - The company aims to expand its pharmaceutical platform and integrate new product lines to strengthen its market position[45]. - The company is actively exploring new product applications and promotions to identify growth opportunities amid market challenges[41]. Governance and Compliance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[112]. - The company emphasizes the independence of its operations from its controlling shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., with no instances of fund occupation or guarantees provided[111]. - The company has established a comprehensive investor relations management system, ensuring timely and accurate information disclosure[115]. - The company has not experienced any significant discrepancies in its governance practices compared to regulatory requirements[116]. - The company maintains a commitment to social responsibility and stakeholder engagement, promoting mutual benefits with suppliers and customers[116]. Strategic Initiatives - The company aims to leverage high-end technology resources globally to expand its business in the regenerative medicine sector[91]. - The company is pursuing mergers and acquisitions to expand its regenerative medicine capabilities, with a focus on careful selection and integration of targets to ensure success[103]. - The company plans to deepen its focus on the regenerative medicine field and enhance its own product brand[92]. - The company is actively pushing for the registration of its product for ulcerative colitis, aiming to expand its pharmaceutical product line[71]. - The company is exploring strategic partnerships and acquisitions to bolster its competitive position in the biotechnology sector[123]. Employee and Social Responsibility - The total number of employees at the end of the reporting period was 586, with 185 in the parent company and 401 in major subsidiaries[147]. - The company has implemented a strict salary policy, providing legal benefits such as social insurance and paid leave to employees[148]. - The company has actively promoted various training programs, including new employee orientation and management training, to enhance employee skills[150]. - In 2022, the company was recognized as a "Charity Loving Enterprise" by the Huangpu District Political and Legal Committee and the Huangpu District Social Construction Promotion Association[168]. - The company emphasizes a green and low-carbon development approach, aiming to optimize internal processes and production techniques to align with national carbon peak and carbon neutrality goals[166].

Financial Performance - The net profit attributable to shareholders for 2022 was -307.84 million yuan, a decrease of 517.76% compared to the previous year[4]. - The total operating revenue for 2022 was 377 million yuan, down 22.84% year-on-year, with artificial crystal revenue decreasing by 74.68% and biological membrane revenue decreasing by 22.92%[5]. - The company's operating revenue for 2022 was ¥377,285,014.20, a decrease of 22.84% compared to ¥488,981,886.96 in 2021[22]. - The net profit attributable to shareholders for 2022 was -¥307,836,656.76, representing a decline of 517.76% from ¥73,687,006.12 in 2021[22]. - The cash flow from operating activities for 2022 was ¥70,983,730.69, down 42.00% from ¥122,394,243.74 in 2021[22]. - The total assets at the end of 2022 were ¥670,209,400.26, a decrease of 39.00% from ¥1,098,737,109.35 at the end of 2021[22]. - The basic earnings per share for 2022 was -¥1.16, compared to ¥0.28 in 2021, reflecting a decline of 514.29%[22]. - The company reported a significant increase in non-recurring losses, with a total of ¥23,807,140.80 in 2022 compared to ¥22,541,099.05 in 2021[29]. - The company experienced a quarterly revenue fluctuation, with Q1 2022 revenue at ¥122,927,958.21 and Q2 at ¥79,949,117.81, indicating a decline in the second quarter[25]. Impairment and Losses - The company recognized inventory impairment losses of 69.05 million yuan and goodwill impairment losses of 214.33 million yuan due to the early termination of the distribution agreement for its subsidiary, Zhuhai Xiangle Medical Equipment Co., Ltd.[4]. - Investment losses of 11.29 million yuan were confirmed from joint ventures and associates, along with long-term equity investment impairment losses of 30.36 million yuan due to economic downturns[4]. - The company recorded an impairment loss of CNY 214.33 million related to goodwill from the acquisition of Zhuhai Xiangle[48]. - The company’s non-recurring gains and losses impacted the net profit attributable to shareholders by CNY 23.81 million in 2022[48]. Research and Development - The company has maintained a focus on innovation in the biopharmaceutical industry, emphasizing the development of biological materials and advanced medical technologies[35]. - The company has established a national-level engineering laboratory for regenerative medical implants, focusing on innovative biomaterials and product development, becoming a leading R&D center in the industry[37]. - The company has authorized 5 invention patents in 2022, focusing on cell technology research and development[45]. - The company’s project for the "Regenerative Biological Membrane High-Tech Industrialization" has been included in the national high-tech industrialization demonstration project[44]. - The company’s cell and stem cell research platform has been built in compliance with international standards, focusing on personalized cell therapy products[45]. - R&D investment amounted to ¥57,899,997.51 in 2022, representing 15.35% of operating revenue, an increase from 10.06% in 2021[74]. - The company is conducting clinical research for the biological dura mater repair material, aiming for product registration and market launch[72]. - The company is in phase III clinical trials for the indication of dermatitis with the product Benvimod, targeting commercialization upon approval[72]. - The company is exploring induced pluripotent stem cells for artificial liver technology, with plans for registration and industrialization[72]. - The company is advancing research on mesenchymal stem cell therapy, with preclinical studies ongoing for various diseases[72]. Market and Product Development - The global pharmaceutical expenditure is projected to reach $1.5 trillion by 2025, with an average growth rate of 4.6% over the next five years[38]. - The Chinese pharmaceutical market is expected to grow at a rate of 14%-17%, surpassing 5.3 trillion yuan by 2025[38]. - The company’s product, Bimekizumab cream, is included in the national medical insurance and is used to treat various autoimmune diseases[39]. - The revenue from Benvimod cream reached CNY 34.35 million, an increase of 14.79% compared to the previous year[47]. - Revenue from cell technology services was CNY 40.45 million, up 73.88% year-on-year[47]. - Revenue from neurosurgery agency products amounted to CNY 79.82 million, reflecting an 11.81% increase from the previous year[47]. - The company is developing a biodegradable tear duct plug for dry eye treatment, with plans for product registration and market launch[72]. - New product launches are anticipated in Q2 2023, focusing on advanced biotechnology solutions aimed at enhancing market competitiveness[122]. Strategic Initiatives - The company plans to forgo cash dividends, bonus shares, and capital reserve transfers to increase share capital for the year[5]. - The company aims to enhance market share through dual-channel marketing strategies, combining online and offline approaches[56]. - The company is actively pursuing collaborations with medical institutions for clinical research projects related to mesenchymal stem cells[51]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the biotechnology market[135]. - The company has established a strategic plan for 2021-2025, focusing on integrating high-end technology resources and expanding into related health fields[92]. - The company plans to continue expanding its product offerings and enhancing its intellectual property portfolio to support future growth[76]. Governance and Compliance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective coordination and checks and balances[109]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirements of relevant laws and regulations[113]. - The company emphasizes investor relations management, ensuring timely and accurate information disclosure through various channels[116]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, and finance[118]. - The company has a comprehensive set of governance regulations, including rules for shareholders' meetings and board meetings, to protect shareholders' rights[111]. - The supervisory board consists of 3 members, including 1 employee supervisor, ensuring compliance and effective oversight of the company's operations[115]. - The company has established specialized committees within the board, including a strategy committee and an audit committee, to provide professional advice and oversight[114]. Employee and Social Responsibility - The total number of employees at the end of the reporting period is 586, with 185 in the parent company and 401 in major subsidiaries[148]. - The company emphasizes a commitment to social responsibility, aiming for high-quality development while ensuring employee welfare and environmental sustainability[165]. - The company adheres to a principle of equal employment opportunities and complies with all relevant labor laws and regulations[166]. - The company has implemented various training programs, including onboarding for new employees and management training, to enhance employee skills and support business goals[151]. - The company actively engaged in social responsibility initiatives, donating materials to local health institutions and supporting businesses with rent reductions in 2022[170]. - The company was awarded the title of "Charity Loving Enterprise" by the Huangpu District Political and Legal Committee and the Huangpu District Social Construction Promotion Association in 2022[170]. Risks and Challenges - The company faces risks from policy changes in the medical device industry, which could impact sales regions and prices, and plans to adapt its marketing strategies accordingly[99]. - The company has established a strict supplier evaluation system to mitigate risks related to animal disease outbreaks affecting raw material supply[103]. - The company has not engaged in any significant asset or equity sales during the reporting period, maintaining its asset base[89]. - The company did not experience any penalties or rectification situations during the reporting period[184]. - There were no major guarantees reported during the period[195]. Future Outlook - The company has provided a performance guidance for 2023, expecting a revenue growth of 25% to 1.875 billion RMB[123]. - The company plans to enhance its digital marketing efforts, aiming for a 50% increase in online engagement by the end of 2023[123]. - Future strategies include diversifying product lines to include at least two new categories by the end of the next fiscal year[128]. - The company aims to leverage its expertise in biotechnology to drive future growth and innovation in the sector[135].

Financial Performance - The net profit attributable to shareholders for 2022 was -307.84 million yuan, a decrease of 517.76% compared to the previous year[4]. - The total operating revenue for 2022 was 377 million yuan, down 22.84% year-on-year, with artificial crystal revenue decreasing by 74.68% and biological membrane revenue decreasing by 22.92%[5]. - The company recognized an inventory impairment loss of 69.05 million yuan and goodwill impairment loss of 214.33 million yuan due to the early termination of the distribution agreement for its subsidiary, Zhuhai Xiangle Medical Equipment Co., Ltd.[4]. - Investment losses from joint ventures and associates amounted to 11.29 million yuan, with long-term equity investment impairment losses of 30.36 million yuan due to economic downturns[4]. - The company's operating revenue for 2022 was ¥377,285,014.20, a decrease of 22.84% compared to ¥488,981,886.96 in 2021[20]. - The cash flow from operating activities for 2022 was ¥70,983,730.69, down 42.00% from ¥122,394,243.74 in 2021[20]. - The total assets at the end of 2022 were ¥670,209,400.26, a decrease of 39.00% from ¥1,098,737,109.35 at the end of 2021[20]. - The basic earnings per share for 2022 was -¥1.16, compared to ¥0.28 in 2021, reflecting a decline of 514.29%[20]. - The company reported a weighted average return on equity of -48.51% for 2022, down 58.24% from 9.73% in 2021[20]. - The company experienced a significant drop in net profit after deducting non-recurring gains and losses, with a figure of -¥331,643,797.56 for 2022, compared to ¥51,145,907.07 in 2021, a decline of 748.43%[20]. - The company reported a total of ¥23,807,140.80 in non-recurring gains for 2022, compared to ¥22,541,099.05 in 2021[27]. Market and Industry Outlook - The global pharmaceutical expenditure is projected to reach $1.5 trillion by 2025, with an average growth rate of 4.6% over the next five years[36]. - The Chinese pharmaceutical market is expected to grow at a rate of 14%-17%, with the industry scale anticipated to exceed 5.3 trillion yuan by 2025[36]. - The global healthcare expenditure is expected to exceed $10 trillion, indicating a significant market opportunity for the company[36]. Product Development and Innovation - The company's core business segments, including biomaterials, pharmaceuticals, and cell therapy, have made significant progress in innovation and production standards during the reporting period[41]. - The company has established a national-level "Regenerative Medical Implant Engineering Laboratory" focusing on the development of new biomaterials[35]. - The company has developed a quality control system for stem cells that meets the standards set by the National Institute for Food and Drug Control[39]. - The company is actively exploring new product applications and promotions to find new growth points amid market challenges[41]. - The company’s flagship drug, Benvimod, is recognized as a first-in-class new drug for treating inflammatory and autoimmune diseases[51]. - The company is conducting clinical research for the biological dura mater repair materials, aiming for product registration and market launch[71]. - The company is in the third phase of clinical trials for the indication of atopic dermatitis with the product Benvimod, targeting commercialization[71]. - The company is exploring induced pluripotent stem cell-derived artificial liver cells for treating acute liver failure, with plans for regulatory submission[71]. - The company is developing a biodegradable tear duct plug for dry eye treatment, with plans to obtain production licenses and achieve commercialization[71]. - The company aims to enhance its product lines in the ophthalmology and pharmaceutical sectors through these R&D initiatives[71]. Research and Development - The company has established a strong R&D platform for cell and stem cell applications, with two GMP-certified cell production lines[50]. - The company invested approximately ¥57.90 million in R&D in 2022, representing 15.35% of its operating revenue, an increase from 10.06% in 2021[73]. - The company has increased its R&D spending capitalization from 5.20% in 2021 to 12.75% in 2022, indicating a strategic shift towards capitalizing R&D expenses[73]. - The company applied for 7 new patents during the reporting period, bringing the total to 118 authorized patents, including 85 invention patents and 33 utility model patents[75]. Governance and Compliance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective coordination and checks and balances[108]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirements of relevant laws and regulations[112]. - The company emphasizes investor relations management, ensuring timely and accurate information disclosure through various channels[115]. - The company maintains complete independence from its controlling shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., in terms of business, personnel, assets, and finance[117]. - The company has a comprehensive set of governance regulations, including the Articles of Association and various operational guidelines[110]. - The supervisory board consists of 3 members, including 1 employee supervisor, fulfilling the requirements of relevant laws and regulations[114]. - The company actively engages with investors through multiple communication channels, enhancing transparency and understanding of its business[115]. Social Responsibility and Sustainability - The company is committed to social responsibility, integrating it into its development strategy and corporate culture[160]. - The company adheres to a "low-carbon, energy-saving, green and healthy" environmental protection philosophy, aiming for high-quality development with a focus on ecological priority and green low-carbon initiatives[167]. - In 2022, the company actively engaged in social welfare, donating materials to local health institutions and supporting businesses with rent reductions, showcasing its commitment to social responsibility[168]. Risks and Challenges - The company faces risks from policy changes in the medical device industry, which could impact sales regions and prices, and plans to adapt its marketing strategies accordingly[98]. - The company is aware of the lengthy process for obtaining product registration certificates, which could affect new product launches and future performance[101]. - The company has established strict supplier evaluation systems to mitigate risks associated with potential animal disease outbreaks affecting raw material supply[102]. Employee and Talent Management - The total number of employees at the end of the reporting period is 586, with 185 in the parent company and 401 in major subsidiaries[147]. - The company adheres to labor laws and provides statutory benefits such as social insurance and paid leave, ensuring employee rights and interests[148]. - Training programs include new employee orientation, frontline talent development, and management training, aimed at enhancing employee skills and capabilities[149]. - The company emphasizes a strong governance structure to protect the rights of shareholders and creditors, ensuring transparency and effective communication[161].

Revenue and Profitability - Revenue for Q1 2023 was CNY 112.68 million, a decrease of 8.33% compared to CNY 122.93 million in the same period last year[5] - Net profit attributable to shareholders was CNY 22.12 million, an increase of 1.54% from CNY 21.78 million year-on-year[5] - Total operating revenue for Q1 2023 was ¥112,684,910.79, a decrease of 8.5% compared to ¥122,927,958.21 in Q1 2022[16] - Net profit for Q1 2023 increased to ¥24,073,789.17, up 12.7% from ¥21,363,230.14 in Q1 2022[18] - The total comprehensive income for Q1 2023 was ¥25,804,745.59, compared to ¥20,843,673.76 in Q1 2022, indicating a growth of 24%[18] Cash Flow and Financial Position - Net cash flow from operating activities decreased by 65.55% to CNY 8.51 million, down from CNY 24.69 million in Q1 2022, primarily due to reduced sales receipts[8] - The company's cash and cash equivalents decreased by CNY 245,729.79, contrasting with an increase of CNY 17.72 million in Q1 2022[8] - The cash and cash equivalents at the end of Q1 2023 were ¥120,070,051.16, down from ¥177,024,470.99 at the end of Q1 2022[22] - The net cash flow from operating activities was ¥8,507,031.19, down 65.5% from ¥24,690,382.91 in the previous year[21] - The company reported a net cash outflow from investing activities of ¥5,714,848.55, compared to a net outflow of ¥2,369,821.21 in the previous year[21] Assets and Liabilities - Total assets increased by 3.50% to CNY 693.67 million compared to CNY 670.21 million at the end of the previous year[5] - The total assets of Guanhao Biotechnology Co., Ltd. as of the end of Q1 2023 amounted to RMB 693,670,565.52, an increase from RMB 670,209,400.26 at the beginning of the year[14] - The company's current assets increased to RMB 324,503,050.37 from RMB 298,889,385.35, reflecting a growth of approximately 8.5%[14] - The total liabilities decreased slightly to RMB 236,985,727.49 from RMB 239,329,307.83, a reduction of approximately 1.4%[15] - The total equity attributable to the parent company increased to RMB 509,156,430.90 from RMB 485,310,208.77, reflecting a growth of approximately 4.9%[15] Accounts Receivable and Expenses - Accounts receivable increased by 38.39% to CNY 99.60 million, attributed to extended credit terms for high-value clients[7] - Accounts receivable rose significantly to RMB 99,604,610.47, up from RMB 71,975,751.81, indicating an increase of about 38.4%[14] - The company reported a decrease in sales expenses to ¥36,778,009.09 from ¥41,645,417.64, a reduction of 11.5%[16] - The company reported a 61.50% reduction in financial expenses, decreasing to CNY 487,811.41 due to a decrease in loan scale and interest[7] - Research and development expenses remained stable at ¥9,567,734.69, slightly down from ¥9,770,941.24[16] Shareholder Information and Corporate Actions - The number of ordinary shareholders at the end of the reporting period was 29,770, with the largest shareholder holding 20.76% of the shares[9] - The company has received approval for a specific stock issuance to targeted investors, as per the resolutions from the board and shareholder meetings[11] Legal Matters - The company is currently involved in a significant lawsuit, with the case still under trial as of the report date[12]

出席本次年度业绩网上说明会的人员有： 董事长张永明先生 证券代码：300238 证券简称：冠昊生物 公告编号：2023-026 冠昊生物科技股份有限公司 关于召开 2022 年度业绩网上说明会的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 冠昊生物科技股份有限公司（以下简称"公司"）《2022 年年度报告全文》 及其摘要经公司第五届董事会第十六次会议和第五届监事会第十三次会议审议 通过，于 2023 年 4 月 20 日刊登在中国证监会指定的创业板信息披露网站上，根 据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关规定，公司定于 2023 年 5 月 5 日下午 15:00 至 17:00 通过远程网络方式召开 2022 年度业绩网上说明会，投资 者可登陆"价值在线"（www.ir-online.cn）参与本次年度业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 ...